Unklare Retinopathie nach intravitrealer Eingabe von Ocriplasmin

S. Abraham; K. Wand; S. Stumpfe; N. Feucht; C. P. Lohmann; M. Maier

doi:10.1007/s00347-015-0080-0

Unklare Retinopathie nach intravitrealer Eingabe von Ocriplasmin

Translated title of the contribution: Unclear retinopathy after intravitreal injection of ocriplasmin

S. Abraham, K. Wand, S. Stumpfe, N. Feucht, C. P. Lohmann, M. Maier

Department of Ophthalmology

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Case report: This article reports the case of a 50-year-old female patient who presented with reduced visual acuity of 0.8 p and metamorphopsia of the left eye caused by focal vitreomacular traction and who was treated with intravitreal Jetrea® (ocriplasmin). After injection the patient suffered from progressive nyctalopia and visual field defects. Electroretinography (ERG) showed decreased amplitudes and optical coherence tomography (OCT) showed decreased reflectivity in the ellipsoid layer that persisted for 2 months after treatment. Conclusion: Before injection of Jetrea® a detailed clarification of such potential side effects is necessary to increase patient compliance in the follow-up.

Translated title of the contribution	Unclear retinopathy after intravitreal injection of ocriplasmin
Original language	German
Pages (from-to)	156-159
Number of pages	4
Journal	Ophthalmologe
Volume	113
Issue number	2
DOIs	https://doi.org/10.1007/s00347-015-0080-0
State	Published - 1 Feb 2016

Access to Document

10.1007/s00347-015-0080-0

Cite this

@article{43d7faace34c47afa8a9bc23454bafbe,

title = "Unklare Retinopathie nach intravitrealer Eingabe von Ocriplasmin",

abstract = "Case report: This article reports the case of a 50-year-old female patient who presented with reduced visual acuity of 0.8 p and metamorphopsia of the left eye caused by focal vitreomacular traction and who was treated with intravitreal Jetrea{\textregistered} (ocriplasmin). After injection the patient suffered from progressive nyctalopia and visual field defects. Electroretinography (ERG) showed decreased amplitudes and optical coherence tomography (OCT) showed decreased reflectivity in the ellipsoid layer that persisted for 2 months after treatment. Conclusion: Before injection of Jetrea{\textregistered} a detailed clarification of such potential side effects is necessary to increase patient compliance in the follow-up.",

keywords = "Optical coherence tomography, Retina, Visual field, Visual loss, Vitreomacular traction",

author = "S. Abraham and K. Wand and S. Stumpfe and N. Feucht and Lohmann, \{C. P.\} and M. Maier",

note = "Publisher Copyright: {\textcopyright} 2015, Springer-Verlag Berlin Heidelberg.",

year = "2016",

month = feb,

day = "1",

doi = "10.1007/s00347-015-0080-0",

language = "Deutsch",

volume = "113",

pages = "156--159",

journal = "Ophthalmologe",

issn = "0941-293X",

publisher = "Springer Medizin",

number = "2",

}

TY - JOUR

T1 - Unklare Retinopathie nach intravitrealer Eingabe von Ocriplasmin

AU - Abraham, S.

AU - Wand, K.

AU - Stumpfe, S.

AU - Feucht, N.

AU - Lohmann, C. P.

AU - Maier, M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Case report: This article reports the case of a 50-year-old female patient who presented with reduced visual acuity of 0.8 p and metamorphopsia of the left eye caused by focal vitreomacular traction and who was treated with intravitreal Jetrea® (ocriplasmin). After injection the patient suffered from progressive nyctalopia and visual field defects. Electroretinography (ERG) showed decreased amplitudes and optical coherence tomography (OCT) showed decreased reflectivity in the ellipsoid layer that persisted for 2 months after treatment. Conclusion: Before injection of Jetrea® a detailed clarification of such potential side effects is necessary to increase patient compliance in the follow-up.

AB - Case report: This article reports the case of a 50-year-old female patient who presented with reduced visual acuity of 0.8 p and metamorphopsia of the left eye caused by focal vitreomacular traction and who was treated with intravitreal Jetrea® (ocriplasmin). After injection the patient suffered from progressive nyctalopia and visual field defects. Electroretinography (ERG) showed decreased amplitudes and optical coherence tomography (OCT) showed decreased reflectivity in the ellipsoid layer that persisted for 2 months after treatment. Conclusion: Before injection of Jetrea® a detailed clarification of such potential side effects is necessary to increase patient compliance in the follow-up.

KW - Optical coherence tomography

KW - Retina

KW - Visual field

KW - Visual loss

KW - Vitreomacular traction

UR - http://www.scopus.com/inward/record.url?scp=84957441283&partnerID=8YFLogxK

U2 - 10.1007/s00347-015-0080-0

DO - 10.1007/s00347-015-0080-0

M3 - Artikel

C2 - 26205745

AN - SCOPUS:84957441283

SN - 0941-293X

VL - 113

SP - 156

EP - 159

JO - Ophthalmologe

JF - Ophthalmologe

IS - 2

ER -

Unklare Retinopathie nach intravitrealer Eingabe von Ocriplasmin

Abstract

Access to Document

Other files and links

Fingerprint

Cite this